PMID- 29133700
OWN - NLM
STAT- MEDLINE
DCOM- 20190711
LR  - 20190711
IS  - 0028-3886 (Print)
IS  - 0028-3886 (Linking)
VI  - 65
IP  - 6
DP  - 2017 Nov-Dec
TI  - Wearing off: A complex phenomenon often poorly recognized in Parkinson's disease. 
      A study with the WOQ-19 questionnaire.
PG  - 1271-1279
LID - 10.4103/0028-3886.217959 [doi]
AB  - BACKGROUND: 'Wearing off' refers to the phenomenology of movement disorders in 
      Parkinson's disease (PD) that appears early and is much commoner than generally 
      believed. It may be present in the form of either motor symptoms or non-motor 
      symptoms. AIM: To investigate the utility of wearing-off questionnaire (WOQ-19, 
      Italian version) in the outpatient clinical practice to assess the suitability of 
      different combinations of treatment, in various stages of PD. METHODS: 73 
      consecutive patients (58% male and 42% female) suffering from PD were recruited 
      through the Santorso Hospital and San Martino Hospital from September 2012 to 
      March 2014. The patients were asked to indicate whether or not they experienced 
      any of the 19 symptoms listed in the questionnaire during the day; if one or more 
      of these referred symptoms relating to PD improved after taking an additional 
      dose of levodopa; and, if these variations were present routinely. Furthermore, 
      we also evaluated the possible correlation between the presence of motor and 
      non-motor symptoms that were listed in the WOQ 19 with the motor impairment 
      assessed by the Hoehn and Yahr stage (HY) and the Unified Parkinson's Disease 
      Rating Scale (UPDRS) part III motor section, in the whole patient cohort as well 
      as in different subgroups undergoing therapy. RESULTS: Among the 73 patients, 22% 
      were receiving levodopa (a mean daily dose of 300 +/- 121.3 mg), 38.3% levodopa and 
      dopamine agonists, 12.3% levodopa/rasagiline, 8.2% levodopa/selegiline, and 19.2% 
      a combination of levodopa/dopamine agonists (DA)/monoamine oxidase inhibitors 
      (MAOI). The most prevalent symptoms were the non-motor symptoms included in the 
      WOQ-19. A significant correlation between the scores obtained on the different 
      motor and non-motor items recorded by the WOQ-19 and the UPDRS motor section and 
      HY scores was found. The therapeutic benefit was especially related to the motor 
      symptoms. DISCUSSION: In clinical practice, this simple and easily administered 
      questionnaire may be useful for the early detection of fluctuations in 
      symptomatology in patients with PD. It will, therefore, help to improve the 
      quality of the global care of patients with PD detected in various stages of the 
      disease.
FAU - Pistacchi, Michele
AU  - Pistacchi M
AD  - Department of Neurology, Santorso Hospital, via Garziere 73, 36014 Santorso, 
      Italy.
FAU - Gioulis, Manuela
AU  - Gioulis M
AD  - Department of Neurology, San Martino Hospital, Belluno, Neurology Service, Viale 
      Europa 22, 32100, Belluno, Italy.
FAU - Sanson, Flavio
AU  - Sanson F
AD  - Department of Neurology, Santorso Hospital, via Garziere 73, 36014 Santorso, 
      Italy.
FAU - Marsala, Sandro Z
AU  - Marsala SZ
AD  - Department of Neurology, San Martino Hospital, Belluno, Neurology Service, Viale 
      Europa 22, 32100, Belluno, Italy.
LA  - eng
PT  - Journal Article
PL  - India
TA  - Neurol India
JT  - Neurology India
JID - 0042005
RN  - 0 (Antiparkinson Agents)
RN  - 0 (Indans)
RN  - 003N66TS6T (rasagiline)
RN  - 46627O600J (Levodopa)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antiparkinson Agents/*therapeutic use
MH  - Cohort Studies
MH  - Female
MH  - Humans
MH  - Indans/therapeutic use
MH  - Levodopa/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Parkinson Disease/diagnosis/*drug therapy
MH  - Surveys and Questionnaires
MH  - Treatment Outcome
EDAT- 2017/11/15 06:00
MHDA- 2019/07/12 06:00
CRDT- 2017/11/15 06:00
PHST- 2017/11/15 06:00 [entrez]
PHST- 2017/11/15 06:00 [pubmed]
PHST- 2019/07/12 06:00 [medline]
AID - ni_2017_65_6_1271_217959 [pii]
AID - 10.4103/0028-3886.217959 [doi]
PST - ppublish
SO  - Neurol India. 2017 Nov-Dec;65(6):1271-1279. doi: 10.4103/0028-3886.217959.